



AN UPDATE ON NEUROPATHIC PAIN MODELS 
Review Article 
 
SEEMA THAKUR, NEHA SRIVASTAVA 
Assistant Professor, Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Near Baddowal Cantt, Ferozepur Road, Ludhiana, 
142021, Punjab, 142021 
Email: thakurseema1983@yahoo.co.in  
 Received: 02 Feb 2016 Revised and Accepted: 20 Apr 2016 
ABSTRACT 
An rodent animal model of pain offers a powerful tool in order to understand the mechanism involved in peripheral nerve injury for preclinical 
study of pain. A battery of neuropathic pain models has been developed to simulate the clinical pain conditions with diverse etiology. This article 
reviews some of the most widely used or promising new models for chronic pain. Partial spinal ligation, chronic constriction injury, and L5/l6 spinal 
nerve ligation represent three of the best-characterized rodent models of peripheral neuropathy. For reasons of reproducibility and simplicity, most 
studies of neuropathic pain are based upon animal models of traumatic nerve injury, usually in the rat sciatic nerve. The present review 
exhaustively discusses the methodology, behavioral alterations of different animal models of neuropathic pain along with their modifications. 
Development of these models has contributed immensely in understanding the chronic pain and underlying peripheral as well as central pathogenic 
mechanisms. 
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INTRODUCTION 
Pain is an unpleasant sensory and emotional experience often 
associated with actual or potential tissue damage, or described in 
terms of such damage [1]. Pain can be of two types: acute pain and 
chronic pain as shown in fig. 1. Acute pain is the pain results from 
disease, inflammation, or injury to tissues whereas chronic pain is 
widely believed to represent disease itself that can be made much 
worse by environmental and psychological factors. Chronic pain 
persists over a longer period of time than acute pain and is resistant 




Fig. 1: Mechanisms of acute and chronic pain 
 
Nociceptive pain is protective and is a normal response to tissue 
injury in comparison to that neuropathic pain is a pathologic or 
maladaptive pain, results from damage to the nervous system, 
producing pain in the absence of stimulation of nociceptors or 
inappropriate response to stimulation of nociceptors [1] often 
characterized by Hyperalgesia (An increased response to a stimulus 
which is normally painful) and Allodynia (Pain due to stimulus 
which does not normally provoke pain). 
The normal pathways involved in the transmission of pain begin 
with stimulation of nociceptors including those that respond to 
chemical irritant stimuli such as the vanilloid receptor VR1, ATP 
purinoceptor P2X3 and noxious heat stimuli such as VR1 and VRL1. 
Signals resulting from intense mechanical and thermal stimulate A-
delta fiber nociceptor and intense mechanical, thermal and chemical 
stimuli stimulate polymodal C-nociceptor.  
Afferent fibers synapse in Rexed’s lamina I, II and V in the spinal cord, 
which is the first level of modulation. Opiate receptors and 
interneurons are present at the dorsal horn. There are also descending 
inputs from the hypothalamus, periaqueductal gray. Opioids, nor-
epinephrine (NE) and serotonin (5-HT3) have modulatory effects on 
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pain transmission. Animal models are being developed to better 
understand the disease pathogenesis and develop drugs for 
neuropathy. In the present review, we have discussed various animal 
models, which may open vistas for developing new drugs to treat 
nephropathy. This led to attempts for developing different nerve 
injury models in animals as surrogates for neuropathic pain (table 1). 
 
Table 1: List of different animal models of neuropathic pain 
Name of model Reference(s) 
Peripheral Nerve Injury  
Chronic constriction injury (CCI) model 2, 3 
Partial sciatic nerve ligation (PSNL) model 5 
L5/l6 spinal nerve ligation (SNL) model 9-11 
L5 spinal nerve ligation 9 
Spare nerve injury (SNI) model 14, 15 
Tibial nerve injury (TNI) model 17 
Spinal nerve transaction (SNT) 18 
Sciatic cryoneurolysis model (SCN) 21, 22 
Sciatic inflammatory neuritis (SIN) model 23 
Sciatic nerve cuffing 24 
Disease related peripheral neuropathy 25, 26 
Postherpetic neuralgia model (PHN) 27-30 
Diabetic neuropathy pain model 25-34 
Cancer pain models  
Chemotherapy-induced peripheral neuropathy models   
Vincristin-induced peripheral neuropathy model (VIPN) 35-37 
Taxol-induced peripheral neuropathy model (TIPN) 39-43 
Cisplatin-induced peripheral neuropathy (CIPN) 44, 45 
Oxaliplatin-induced peripheral neuropathy (OIPN) 46, 47 
Bone cancer pain models  
Rat tibial bone cancer model (TBC) 48, 49 
Mouse femur bone cancer pain model (FBC) 50 
Mouse calcaneous bone cancer pain model (CBC)  50, 51 
HIV-induced neuropathy models 52-55 
HIV gp-120 associated sensory neuropathy 53-58 
Antiretroviral drug-induced sensory neuropathy  
Antiretroviral toxic neuropathy (ATN) model 59, 60 
 
Animal models of neuropathic pain 
Peripheral nerve injury models 
Chronic constriction injury (CCI) model  
CCI is the most commonly used and highly validated model. Bennett 
and Xie reported a rat model unilateral mononeuropathy in 1988. 
Briefly, the rats are anesthetized with pentobarbital (40 mg/kg) 
sodium. The common sciatic nerve is exposed at the level of the 
middle of the thigh by blunt dissection through biceps femoris. 
proximal to the sciatic’s trifurcation, about 7 mm of nerve was freed 
of adhering tissue and 4 ligatures (4.0 chromic gut) are tied loosely 
around it at a distance of about 1 mm spacing [2, 3]. After surgery, 
all animals were administered gentamicin (5 mg/kg) to prevent 
sepsis. Neuropathic pain symptoms such as hyperalgesia and 
allodynia developed from day 3 after surgery and persisted for 7 mo 
[3, 4].  
Partial sciatic nerve ligation (PSNL) model  
Seltzer et al. reported a rat model of partial sciatic nerve ligation in 
1990. In this model, the right sciatic nerve is exposed at the high-
thigh level and ligated so that 1/3-1/2 thickness of the sciatic nerve 
is trapped in the ligature [5]. Symptoms of neuropathic pain i. e 
hyperalgesia and allodynia develop immediately after injury i. e 1 hr 
after injury and symptom develops for at least 7 mo [6, 7] as well as 
these symptoms seen in human causalgia patients. In this method, 
the animal also shows mirror image pain in which pathological 
nociception occurs on the side contralateral to the injured side. The 
sensitivity of this method is 61℅ [8].  
L5/l6 spinal nerve ligation (SNL) model  
Kim and Chung reported another unilateral mono neuropathic rat 
model in 1992. In this model, the unilateral ligation of two spinal 
nerves (L5 and L6) is performed under thiopental sodium 
anesthesia (50 mg/kg). Briefly, the left paraspinal muscles are 
separated from the spinous process at the L4-S2 levels. The L6 
transverse process is removed to identify the L4-L6 spinal nerves 
visually. The left L5 and L6 spinal nerves is isolated and tightly 
ligated with 6-0 silk thread. After that the wound is sutured [9-11]. 
Symptoms developed immediately after injury and maintained for at 
least 4 mo [12] as well as symptoms seen in human causalgia 
patients. Animals also show mirror-image pain similar to those of 
Seltzer model. All three models i. e CCI, PSNL and SNL can be 
produced in mice, and a direct comparison of these three models has 
been reported [13]. Authors demonstrated a similar onset of sensory 
threshold changes in mechanical and cold allodynia in all three 
models, but a greater magnitude of change in sensory threshold in 
SNL. All three models demonstrated significant cold and mechanical 
allodynia at 3 d after injury and spontaneous pain at one day after 
the injury. Mechanical allodynia was determined by the application 
of an 8.4 mN Von-Frey hair. The allodynia was greatest in SNL model 
with a ~ 80% response frequencies, followed by PNL (~60% 
response frequency) and CCI (~45% response frequency). They also 
demonstrate a more significant involvement of the sympathetic 
nervous system component in sensory response to SNL than 
following PNL or CCI. The sensitivity of this method was 68℅ [8]. 
L5 spinal nerve ligation  
Kim and Chung also reported the single L5 nerve ligation. In this 
method, left L5 spinal nerve is tightly ligated 5 mm distal to the dorsal 
root ganglia with 4-0 Mersilk [9]. This method is much easier to 
perform than L5/l6 ligation. This method is also performed in mice. 
Spare nerve injury (SNI) model  
Decosterd and Woolf reported the rat model of spared nerve injury 
in 2000. Briefly, the rat is anaesthetized with chloral hydrate (80 
mg/kg i. p) and skin of the left lateral thigh was incised. The cranial 
and the caudal parts of biceps femoris muscles are separated and 
held apart by retractor to expose the sciatic nerve and its three 
branches: the sural, common peroneal and tibial nerves. The tibial 
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and common peroneal nerves are tightly ligated with 4/0 silk and 2-
3 mm of the nerve distal to the ligation was removed. Any stretching 
or contact with the intact sural nerve is avoided. Then the skin and 
muscle is sutured [14, 15]. This method produces robust changes in 
behavioral symptoms i. e allodynia and hyperalgesia [6, 7]. 
Symptoms of neuropathic pain developed immediately after surgery 
and maintained for at least 7 mo [16]. 
Tibial nerve injury (TNI) model  
The tibial nerve injury model is a novel, surgically uncomplicated, 
rat model of neuropathic pain based on a unilateral transaction 
(neurotomy) of the tibial branch of the sciatic nerve. Tibial nerve 
injury was performed under pentobarbital anaesthesia. Distal to the 
trifurcation of the left sciatic nerve, the tibial branch of the sciatic 
nerve is ligated, whereas the sural and common peroneal nerves 
remained uninjured [17]. Behavioral symptoms develop within 2 w 
after surgery and persist for at least 9 w.  
Spinal nerve transection (SNT)  
In this model, unilateral mononeuropathy is produced according to 
the method of described earlier by Colburn et al. [18]. Briefly, rats 
are anesthetized with halothane in an oxygen carrier (induction 4 %, 
maintenance 2 %). A small incision to the skin overlying L5-S1 is 
made followed by retraction of the paravertebral musculature from 
the vertebral transverse processes. The L6 transverse process is 
partially removed exposing the L4 and L5 spinal nerves. Then the L5 
spinal nerve is identified, lifted slightly, and transected [19]. The 
wound is irrigated with saline and closed in two layers with 3-0 
polyester suture and surgical skin staples.  
Sciatic cryoneurolysis model (SCN)  
SCN was performed as described by De Leo et al. [21, 22]. Briefly, a 
segment (-1.0 cm) of the common sciatic nerve proximal to its 
primary trifurcation is exposed by blunt dissection and suspended 
across forceps in the surgical opening. The nerve is lesioned in a 30-
s freeze, 5-s thaw, and 30-s freeze cycle using a 2-mm diameter 
cryoprobe cooled to-60 °C with nitrous oxide as the refrigerant. The 
nerve is allowed to thaw and then returned to its natural position. 
The wound is closed with surgical staples and the animal recovered 
in room air. This model shows a little difference in pain behaviour in 
the first 7 d after injury [21, 22]. One potential advantage of this 
method is that cryoneurolysis-induced nerve injury may be reversible, 
thus providing an opportunity to study the effect of transient nerve 
injury and the healing process. Behavioral symptoms such as touch-
evoked allodynia last for about 15-21 d as compared to other 
peripheral injury models such as CCI, SNL and PSNL. 
Sciatic inflammatory neuritis (SIN) model  
Apart from trauma of peripheral nerve, most of the neuropathies 
developed by inflammation or infection. Chacur et al. reported a new 
model of sciatic inflammatory neuritis in 2001. In this method, 
firstly the peri-sciatic catheter is implanted then after the injection 
of zymosan (40, 80 and 160 μg) is given bilaterally around sciatic 
nerve [23]. Allodynia was observed 24 h after surgery. Thermal 
hyperalgesia cannot be detected in the SIN. Peri-sciatic immune 
activation can also be done by placing dead bacteria, carrageenan, 
LPS and FCA, proinflammatory gut sutures on the sciatic nerve and it 
produces both hyperalgesia and allodynia [20]. 
Sciatic nerve cuffing  
Benbouzid [24] reported the model of sciatic nerve cuffing, a model of 
sustained neuropathic pain in mice in 2007. Briefly, in this method 
surgery is done under aseptic conditions and ketamine/ xylazine 
anesthesia (ketamine: 17 mg/ml, i. p., xylazine: 2.5 mg/ml, i. p., 4 ml/kg).  
The common branch of the right sciatic nerve is exposed and a 2 mm 
long splitted section of polyethylene tubing (ID = 0.38 mm, ED = 1.09 
mm; PE-20) is placed around it (Cuff group). The shaved skin layer is 
closed using suture. Thermal hyperalgesia and allodynia develop on 
day 1 and heat hyperalgesia persists for 2 w but mechanical 
allodynia persists for 2 mo. Sciatic nerve cuffing in mice is a 
pertinent model for the study of nociceptive and emotional 
consequences of sustained neuropathic pain. 
Disease related peripheral neuropathy 
In humans, shingles and diabetes are a very common disease with 
neuropathic symptoms (25). Shingles is characterised by a very 
painful rash. Some patient suffers from postherpetic neuralgia 
following acute shingles, which can persist for many years and even 
for life. Diabetes is associated with increased risk of a number of 
well-known microvascular complications (eg, retinopathy, 
nephropathy, and neuropathy) and macrovascular complications 
(eg, stroke, coronary heart disease, peripheral vascular disease) 
[26]. Diabetic peripheral neuropathy (DPN) is probably the most 
common of the microvascular complications, affecting 
approximately 50% of persons with diabetes. Although 
hyperglycemia is clearly important in the development of 
neuropathy, the pathophysiological processes by which 
hyperglycemia causes neuropathy are not fully understood. Recent 
evidence suggests that hyperglycemia contributes to a state of 
heightened oxidative stress and the generation of reactive oxygen 
species that are important in the development of neuropathy and 
other microvascular diabetes complications [25, 26]. Several 
metabolic pathways probably contribute to hyperglycemia-induced 
oxidative stress, including the polyol pathway, protein kinase C 
(PKC) activation, and accumulation of the end products of auto 
glycation (ie, advanced glycation end products). 
Postherpetic neuralgia model (PHN)  
Postherpetic neuralgia [27] is characterized by the presence of both 
spontaneous and evoked pain symptoms such as burning and aching 
and often superimposed by allodynia. In a rodent model of varicella 
zoster virus [28-30], VZV is propagated on fibroblast (primary 
human embryonic lung) cells and harvested when cells exhibited 
approximately 80% cytopathic effect (cpe) on microscopy 
(equivalent to 104 to 105 plaque forming units, pfu). Cpe refers to 
the destruction of normal fibroblast cell architecture due to viral 
lytic infection and is characterized by the presence of vacuoles and 
granules. Virus-infected cells are gently scraped from the flask 
surface onto which they had formed a monolayer culture, and the 
cell suspension is centrifuged at 1500 r. p. m. 4 °C for 15 min. The 
resulting pellet from each 75 cm2 flask was resuspended in 150 μl 
sterile phosphate buffer solution. Animal are then anesthetized with 
pentobarbitone, 40 mg/kg i. p and then s. c. injected with 50 μl viral 
inoculums into the mid-plantar glabrous footpad of the left 
(ipsilateral) hind limb using a 25 gauge needle. Control animals 
received a similar injection of uninfected fibroblast cells (mean 
count 6–8x 106 cells/75 cm2 flasks). Virus-induced neuropathic pain 
symptom i. e mechanical allodynia develops on day 4 and remains 
for 6 w [31]. This model will prove useful in elucidating the 
pathophysiology of zoster-associated pain and provide a tool for 
pre-clinical screening of analgesic drugs [31]. 
Diabetic neuropathy pain model  
The most commonly and widely used chemically-induced model of 
diabetic neuropathy is streptozotocin-induced diabetic neuropathy. 
Streptozotocin is a chemotherapeutic agent and it kills insulin-
secreting islet cells. Briefly, diabetes is induced in rats by single 
injection of STZ (45-75 mg/kg i. p) dissolved in citrate buffer (pH-
4.5-5.5) [25, 31]. Diabetes is observed 48-72 hr after the injection of 
STZ by measurement of blood glucose levels [31]. Other transgenic 
models of diabetic neuropathy such as insulin deficient BB rats [32, 
33] and NOD mice [34] insulin resistant ob/ob and db/db mice, the 
Mongolian gerbil (‘sand rat’). Experimental Diabetic neuropathy is 
often characterized by hyperalgesia, allodynia, along with motor 
deficits and reduced axonal and nerve conduction velocity. 
Cancer pain models  
Cancer-related pain may be caused by tumor infiltration or 
compression of nerve, plexus, or roots, immunoreactive and 
pronociceptive substances released from rumors, or by treatment 
(chemotherapy, radiation, or surgery). 
Chemotherapy-induced peripheral neuropathy models  
Major and severe side effects of chemotherapy are peripheral 
neuropathy and bone marrow suppression. Various classes of 
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chemotherapeutic agent particularly the vinca alkaloids, platinum 
compounds and taxol are responsible for causing toxicity 
particularly the neurotoxicity and also inducing neuropathy. When 
these chemicals are administered to an animal, they produce 
neuropathy which may be used to study causes, prevention and 
treatment of their neurotoxicity. 
Vincristine-induced peripheral neuropathy model (VIPN)  
Vincristine, a vinca alkaloid, is mainly used to treat cancer 
particularly acute leukemia, Kaposi sarcoma, Hodgkin disease and 
other lymphoma. It acts by binding to tubulin protein and inhibits 
microtubule polymerization, thus causing the mitotic arrest. Severe 
neuropathies result from vincristine administration, so it is a 
limiting factor for dose escalation which is often needed to achieve 
the desired anti-cancer activity. Several methods have been 
described to induce neuropathic pain by vincristine [35-37]. Daily 
injection of vincristine (single doses of 50, 100 and 200 μg/kg) for 
10 d (5 consecutive drug days+2 drug-free days+5 more drug days) 
in rat produces the symptoms of hyperalgesia and allodynia. 
Continuous intravenous vincristine infusion can also produce 
allodynia, but does not shows the symptoms of hyperalgesia [35-38]. 
The reason for this remains to be clarified. 
Taxol-induced peripheral neuropathy model (TIPN)  
Paclitaxel is a chemotherapeutic agent obtained from the pacific yew 
tree Taxus breviforia and is used to treat ovarian and breast cancer, 
and non-small cell lung cancer. It acts by binding to tubulin (at a site 
different from vinca alkaloid) and blocks the polymerization of 
microtubules. It produces the dose-dependent neuropathy and 
incidence is 50-90℅. Several rat or mouse model of taxol-induced 
neuropathic pain model have been reported. Briefly, Paclitaxel (2 
mg/kg i. p) was administered on four alternative days (days 0, 2, 4 
and 6) to rats and it produces the symptoms of thermal hyperalgesia 
and allodynia [39-43].  
Cisplatin-induced peripheral neuropathy (CIPN)  
Cisplatin (CDDP) and the other platinum-derived drugs are among 
the most effective antineoplastic agents, but they are severely 
neurotoxic. The clinical features of CDDP neurotoxicity in humans 
are mainly ataxia, pain, and sensory impairment secondary to 
accumulation of CDDP in the dorsal root ganglia (DRG) and 
subsequent damage, resulting in secondary nerve fiber 
axonopathy. Severe neuropathy can occur in 3% to 7% of treated 
cases with single agents but can increase to 38 % with combined 
regimens. Peripheral neuropathy induced by injection of cisplatin 
at a dose of 2 mg/kg i. p. twice weekly for 8 times using a volume 
of 4 ml/k [44, 45].  
Oxaliplatin-induced peripheral neuropathy (OIPN)  
Oxaliplatin is a third-generation platinum-based chemotherapeutic 
agent used to treat advanced metastatic colorectal cancer, ovarian 
and breast cancer, and lung cancer. It is structurally similar to 
cisplatin but contains a 1, 2-diaminocyclohexane carrier ligand. This 
modification enhances the antitumor activity. Since it is a platinum 
derivative, oxaliplatin induces neurotoxicity but not the 
nephrotoxicity, as with cisplatin. Several models have been reported 
in rat as well as in mice. Briefly, oxaliplatin induces neuropathy by i. 
v injection at one of the three different doses, i. e 1, 2 or 4 mg/kg, 
twice weekly for four-and-a-half consecutive weeks [46, 47]. It 
shows the both hyperalgesia and allodynia [6, 7].  
Bone cancer pain models  
Bone cancer pain is one of the most common cancer-related pains. 
Bone cancer can be primary or metastatic from the breast, prostate, 
ovary and lung tumors. Deep pain with a burning and stabbing 
sensation is often described by bone cancer patients. 
Rat tibial bone cancer model (TBC)  
In this model, MRTT-1 rat mammary gland carcinoma cells are 
injected into the tibial bone of rats [48]. MRTT-1 rat mammary gland 
carcinoma cells are prepared by culturing the cells in the medium 
containing RPMI 1640, 10 % l-glutamine and 2 % penicillin/ 
streptomycin. Cells are then released from the plastic by brief 
exposure to 0.1 % w/v trypsin and then prepared for injection. Ten 
millimeters of the medium is centrifuged for 3 min at 1200 rpm, and 
the resulting pellet is washed twice with 10 ml of Hank’s balanced 
salt solution without Ca2+, Mg2+ or phenol red and then centrifuged 
for 3 min at 1200 rpm. The final pellet is then suspended in 1 ml of 
Hank’s solution and cells are counted by using a hemocytometer. 
Cells are then diluted to achieve final concentrations for injection 
and keep in ice until injection. Destruction of bone can be identified 
within 10 d of tumor cell injection. Behavioral symptoms i. e 
hyperalgesia and allodynia develops 10-12 d after tumor cell 
injection. Bisphonate such as Zoledronate and cyclooxygenase 
(COX)-2 are effective in attenuating the mechanical hyperalgesia and 
allodynia on chronic treatment [49].  
Mouse femur bone cancer pain model (FBC)  
In this model, osteolytic mouse sarcoma NCTC2472 cells are used to 
produce bone cancer by injecting tumor cells into the marrow space 
of the femur bone and then sealing the injection site [50]. Bone 
destruction and osteoclastogenesis occurs 5 d after the injection. 
Spontaneous pain symptoms such as flinching, nocifensive behavior 
as well as changes in the neurochemical marker develops within 14 
d. Drugs like opioids and COX-2 inhibitors are effective in reversing 
these symptoms. But the effect of COX-2 inhibitors in this model is 
different from TBC model suggests that different bone cancer 
models have different pathophysiology which is based upon animal 
species, tumor type, and location. 
Mouse calcaneous bone cancer pain model (CBC)  
This model is similar to FBC model, except that NCTC2472 cells are 
injected into mouse calcaneous bone [50]. Symptoms such as 
osteolysis, spontaneous pain i. e-paw licking and evoked pain i. e 
mechanical and cold allodynia occurs 6 d after implantation and 
remains for at least 16 d [50, 51]. 
HIV-induced neuropathy models  
Distal symmetrical polyneuropathy (DSP) afflicts 15–50% of people 
living with HIV [52], 50–60% of whom have measurable sensory 
abnormalities and on-going, paroxysmal or stimulus-evoked pain 
associated with HIV infection and is characterized by length-
dependent axonal degeneration of sensory fibers [53, 54]. There are 
two predominant (and clinically similar) settings in which painful 
HIV-DSP may occur. First, a disease-related DSP associated with 
HIV-infection per se; or secondly a drug-induced DSP associated 
with the use of nucleoside reverse transcriptase inhibitors (NRTI), 
particularly the dideoxynucleosides; zalcitabine (ddC), didanosine 
(ddI) and stavudine (d4T), as part of highly active anti-retroviral 
therapy (HAART) [53, 54]. The neuropathy in these rodents is 
characterized by distal degeneration of unmyelinated sensory axons, 
similar to the “dying back” pattern of C-fiber loss seen in patients 
with HIV-SN. This model will be useful in examining mechanisms of 
distal axonal degeneration and testing potential neuroprotective 
compounds that may prevent the development of the sensory 
neuropathy [55, 56]. 
HIV gp-120 associated sensory neuropathy  
A distal symmetrical sensory peripheral neuropathy is frequently 
observed in people living with Human Immunodeficiency Virus Type 
1 (HIV-1). This neuropathy can be associated with viral infection 
alone, probably involving a role for the envelope glycoprotein 
gp120; or a drug-induced toxic neuropathy associated with the use 
of nucleoside analogue reverse transcriptase inhibitors as a 
component of highly active anti-retroviral therapy. In this method, 
briefly, under 1–2% isoflurane anaesthesia in O2 and N20, and 
aseptic surgical conditions, the left sciatic nerve is exposed in the 
popliteal fossa without damaging the perineurium and wrapped 
loosely, with a 3-0.5 cm2 strip of oxidized regenerated cellulose; 
previously soaked in 200 μl of a 0.1% rat serum albumin (RSA) in 
saline solution containing 200ng gp120-MN or for sham controls; 
0.1% RSA in saline. Then nerve was gently manipulated back into 
place and incisions closed with 4/0 sutures. Animal shows 
mechanical hypersensitivity on day 14 and it persists for 43 d [53, 
55]. There is enhanced mechanical hypersensitivity by combining 
Thakur et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 6, 11-16 
15 
perineural HIV gp-120 and didanosine (50 mg/kg in saline) at the 
time of surgery and three times a week thereafter for a maximum of 
3 w [58].  
Antiretroviral drug-induced sensory neuropathy  
The prevalence of peripheral neuropathy has increased among 
HIV/AIDS patients with the greater use of nucleoside reverse 
transcriptase inhibitors (NRTIs), particularly zalcitabine (ddC), 
stavudine (d4T) and didanosine (ddI), leading to the recognition of 
the disorder, termed antiretroviral toxic neuropathy (ATN). 
Antiretroviral toxic neuropathy (ATN) model  
In this, there is combined ex vivo and in vivo models of ATN-induced 
by didanosine (ddI) following infection by the lentivirus, feline 
immunodeficiency virus (FIV). Briefly, Specific pathogen-free 
neonatal (day 1) kittens are infected with 0.2 ml of infectious (104 
TCID50/ml) or heat-inactivated virus in accordance with CCAC 
guidelines, as described previously [59]. FIV-infected and mock-
infected animals are treated with ddI (33 mg/kg daily) by oral 
gavage starting at 6 w post-infection until 12 w post-infection.  
This treatment causes axonal injury and associated neuro-
behaviour changes. ddI mediates ATN through mitochondrial 
injury in neurons. The FIV strain used in this study was an 
infectious neurovirulent recombinant molecular clone, V1-Ch, 
derived by transfection of CrFK cells and amplification in feline 
peripheral blood mononuclear cells (PBMCs), as described 
previously. Culture supernatants from FIV-infected feline PBMC, 
which served as sources of infectious virus for these experiments, 
were cleared of cellular debris by centrifugation and titered by 
limiting dilution, as described previously [59]. 
CONCLUSION 
During the past few decades, the use of animal models has open 
vista to understand the pathogenesis of neuropathy. Important 
pathogenic mechanisms still remain active and unmodified by 
present therapeutic strategies. So, this update will help to explore 
new therapeutic interventions in the management of NP. 
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